New 'Cold' ablation device aims to zap heart rhythm problems without heat
NCT ID NCT07018596
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new device called the CellFX nsPFA catheter, which uses short electrical pulses instead of heat to treat paroxysmal atrial fibrillation (a type of irregular heartbeat). The goal is to see if it is safe and effective at restoring normal rhythm in 215 adults who have not responded well to medication. The procedure targets the heart's pulmonary veins to block faulty signals.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CellFX nsPFA Cardiac Catheter System (device using nanosecond pulsed field ablation)
What this could lead to
If successful, this could offer a safer, more precise way to treat atrial fibrillation without heat, potentially reducing complications and improving recovery.
What could go wrong
This is an early-stage device trial with 215 participants, so results may not apply to everyone. Risks include stroke, heart damage, or other serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Na Homolce Hospital
RECRUITINGPrague, Roentgenova, 37/2, Czechia
Contact
Contact